A detailed history of Hollencrest Capital Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hollencrest Capital Management holds 1,334 shares of GILD stock, worth $121,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,334
Previous 1,331 0.23%
Holding current value
$121,860
Previous $91,000 21.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$66.59 - $83.99 $199 - $251
3 Added 0.23%
1,334 $111,000
Q4 2023

Feb 14, 2024

BUY
$73.27 - $83.09 $36,781 - $41,711
502 Added 60.55%
1,331 $107,000
Q4 2022

Feb 06, 2023

BUY
$62.32 - $89.47 $51,663 - $74,170
829 New
829 $71,000
Q1 2022

Apr 18, 2022

SELL
$57.92 - $72.58 $846,153 - $1.06 Million
-14,609 Closed
0 $0
Q4 2021

Jan 07, 2022

BUY
$64.88 - $73.64 $84,344 - $95,732
1,300 Added 9.77%
14,609 $1.06 Million
Q3 2021

Oct 13, 2021

BUY
$67.69 - $73.03 $900,886 - $971,956
13,309 New
13,309 $929,000
Q2 2020

Jul 16, 2020

SELL
$72.34 - $84.0 $911,266 - $1.06 Million
-12,597 Closed
0 $0
Q1 2020

May 01, 2020

SELL
$62.63 - $80.22 $116,992 - $149,850
-1,868 Reduced 12.91%
12,597 $942,000
Q4 2019

Jan 23, 2020

BUY
$61.62 - $67.78 $191,022 - $210,118
3,100 Added 27.28%
14,465 $940,000
Q3 2019

Oct 23, 2019

BUY
$62.51 - $69.0 $506,331 - $558,900
8,100 Added 248.09%
11,365 $720,000
Q1 2018

Apr 24, 2018

BUY
$72.84 - $88.8 $3,059 - $3,729
42 Added 1.3%
3,265 $246,000
Q4 2017

Jan 19, 2018

SELL
$71.15 - $83.52 $412,670 - $484,416
-5,800 Reduced 64.28%
3,223 $0
Q3 2017

Oct 10, 2017

BUY
$72.11 - $85.47 $650,648 - $771,195
9,023
9,023 $731,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Hollencrest Capital Management Portfolio

Follow Hollencrest Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hollencrest Capital Management with notifications on news.